-
Who is eligible for the new RSV vaccine?
The NHS RSV vaccination program prioritizes pregnant women from 28 weeks of gestation and adults aged 75 and older. This targeted approach aims to protect those most at risk of severe complications from RSV, particularly during the winter months when the virus is most prevalent.
-
What are the expected outcomes of the NHS vaccination program?
The NHS aims to prevent an estimated 5,000 hospitalizations annually in infants due to RSV. Studies suggest that the vaccine can lead to a 70% reduction in severe lung infections among vaccinated newborns, significantly lowering the burden of RSV during peak seasons.
-
How does RSV impact vulnerable populations during winter?
RSV is particularly dangerous for infants and the elderly, leading to around 30,000 hospital admissions for infants each winter. The virus can cause severe respiratory issues, making it crucial to protect these vulnerable groups through vaccination.
-
What are the symptoms of RSV?
Symptoms of RSV can range from mild cold-like signs to severe respiratory distress. Common symptoms include coughing, wheezing, difficulty breathing, and fever. In severe cases, RSV can lead to bronchiolitis or pneumonia, especially in high-risk populations.
-
How can I get the RSV vaccine?
Eligible individuals, including pregnant women and older adults, can receive the RSV vaccine through their local NHS services. It's advisable to check with healthcare providers for specific details on availability and scheduling.
-
What should I do if I suspect RSV infection?
If you suspect an RSV infection, especially in vulnerable individuals, it's important to seek medical advice promptly. Healthcare providers can offer guidance on management and treatment options to mitigate severe symptoms.